Previous close | 8.70 |
Open | 8.80 |
Bid | 4.80 |
Ask | 7.30 |
Strike | 105.00 |
Expiry date | 2024-07-19 |
Day's range | 8.70 - 8.80 |
Contract range | N/A |
Volume | |
Open interest | 18 |
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the significant real-world burden of systemic mastocytosis (SM), and highlight the durable clinical outcomes of AYVAKIT®/AYVAKYT® (avapritinib) across the spectrum of the disease. The presentations, which build on over a decade of pioneering research with clinical experts and patient advocates, will be reported at the following meetings:
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an app
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...